P-006

P-006 is an investigational drug candidate currently in development by Pangea Pharmaceuticals for the treatment of muscle spasms. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development and commercialization of reformulated or generic products, often utilizing the FDA's 505(b)(2) regulatory pathway to improve upon existing therapies. While the specific active pharmaceutical ingredient (API) and molecular mechanism of action for P-006 have not been publicly disclosed, the product is part of Pangea's pipeline targeting pain management and neuromuscular conditions. The company's strategy typically involves the development of products with improved pharmacokinetic profiles or alternative delivery methods compared to established therapeutic agents.